🇺🇸 Insulin Lispro Protamine Suspension in United States
118 US adverse-event reports
Safety signals — FAERS
Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.
- Window: 22 April 2025 – 22 April 2026
- Total reports: 118
Most-reported reactions
- Blood Glucose Increased — 16 reports (13.56%)
- Vomiting — 15 reports (12.71%)
- Drug Ineffective — 12 reports (10.17%)
- Hepatic Enzyme Increased — 12 reports (10.17%)
- Arthralgia — 11 reports (9.32%)
- Swelling — 11 reports (9.32%)
- Therapeutic Response Decreased — 11 reports (9.32%)
- Gait Disturbance — 10 reports (8.47%)
- Oedema Peripheral — 10 reports (8.47%)
- Pain In Extremity — 10 reports (8.47%)
Other Diabetes approved in United States
Frequently asked questions
Is Insulin Lispro Protamine Suspension approved in United States?
Insulin Lispro Protamine Suspension does not currently have US marketing authorisation in our dataset.
Who is the marketing authorisation holder for Insulin Lispro Protamine Suspension in United States?
Eli Lilly and Company is the originator. The local marketing authorisation holder may differ — check the official source linked above.